AI-Immunology™ Platform We strive to develop novel drugs with an unprecedented level of efficacy and precision. Using AI, we simulate the human immune system and generate predictive models to identify and develop personalized and other next-generation immunotherapies for patients.
ONCOLOGY
PIONEER™ is a proprietary AI-Immunology™ model for the rapid discovery of patient-specific neoantigens used for our personalized cancer immunotherapies. We want to challenge and improve the standardized therapies of today, where one size fits all, risking unspecific immune activation. With our AI-Immunology™ platform, we seek out and target cancer cells, creating truly personalized therapies where one size fits one and only one.
Related Resources
Sep 20, 2023
Press releases
Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea
Sep 18, 2023
Press releases
Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company
Sep 11, 2023
Press releases
Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development
Mar 27, 2023
Publications
Endogenous viral elements constitute a complementary source of antigens for personalized cancer immunotherapy
Subscribe to our Newsletter
Be the first to know about news, milestones and events at Evaxion by subscribing to our newsletter. You'll only hear from us when it's important, and can unsubscribe at any time.